Journey Medical, Padagis US Reach Settlement Agreement for Qbrexza, Amzeeq, Zilxi Patent Exclusivity

MT Newswires · {{timeTz}}

10:00 AM EDT, 05/24/2022 (MT Newswires) -- Journey Medical Corporation (DERM) said Tuesday that it has reached an agreement with Padagis US to settle the patents covering Qbrexza for the treatment of primary axillary hyperhidrosis, Amzeeq for the treatment of severe acne, and Zilxi for the treatment of rosacea.

The commercial-stage pharmaceutical company said that Padagis will not be permitted to launch generic versions of the three products until 2030, 2031, and 2027, respectively.

Price: 3.64, Change: -0.38, Percent Change: -9.45

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top